All News

This month, we spoke with Aaron Johnson, a fourth-year pharmacy student a the Nova Southeastern University College of Pharmacy.

When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures significantly decline.

Quiz questions to assess your knowledge on common treatments for cold sores.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Zantac can treat and prevent heartburn, as well as treating stomach ulcers, gastroesophageal reflux disease, and conditions that cause too much stomach acid.

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.

Medicaid expansion implementation was associated with a decrease in the number of uninsured patients from 6.7% pre-expansion to 3.6% post-expansion.

MIS-C is a rare complication of SARS-CoV-2 infection, which is characterized by symptoms such as fever, multiorgan involvement, and documented SARS-CoV-2 exposure.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses points of note in the evolution of lymphoma classification during her clinical and investigational research on the subject.

Heart-related complications in children with COVID-19 are uncommon, but case reports have noted cardiogenic shock, myocarditis, pericarditis, and arrhythmias.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

David Pope, PharmD, CDE, chief innovation officer at OmniSYS, discusses some of the technology trends that occurred in the pharmacy space during the pandemic.

In this month's episode, Staci Rush, clinical pharmacy technician at Hometown Pharmacy, discusses pharmacy intervention and how it can reduce hospital readmissions for patients.

Invega Hafyera is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

Theraful is a cold and flu medication that may help to relieve symptoms such as congestion, sore throat, aching, and fever.

An earlier clinical trial found a higher number of acute myocardial infarction events in those administered HepB-CpG vaccine versus those administered the HepB-alum vaccine.

Rita Roy, MD, CEO of the National Spine Health Foundation, discusses some alternative treatment plans for chronic back pain to help address the opioid epidemic.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.

Mylo Wells, PharmD, owner of Wells Hometown Drug and Wells Hometown Drug Keosauqua, aims to give back to the community where he grew up.

New therapies and combination regimens may allow a more tailored approach.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses key takeaways from the HOPA 2022 annual conference.

CDI is the leading cause of diarrhea in hospitalized patients.

PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.

The companies have decided to unblind the trial and perform no additional analyses for the OS endpoint because there was no clinical benefit observed in the doublet therapy arm.